The National Comprehensive Cancer Network and the NCCN Foundation announced five new recipients for the 10th annual NCCN Foundation Young Investigator Awards Program.
G. David Roodman, an Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher, received a five-year, $1.6 million grant from the National Cancer Institute to study ways to build bone and decrease tumor growth in multiple myeloma bone disease.
MD Anderson Cancer Center and Innovent Biologics Inc. signed an agreement to co-develop TYVYT (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, in rare cancers in the U.S.
UCLA researchers have launched a phase II trial that uses TMPRSS2, a hormone suppressor commonly used to treat prostate cancer, to improve clinical outcomes for men infected with COVID-19.
A telesitevisit? No, this is not a typo.
Programs designed to meet the NCI Community Outreach and Engagement requirements for cancer center designation have positioned the University of Miami Sylvester Comprehensive Cancer Center to monitor the prevalence of SARS-CoV-2 in South Florida.
In Georgia, COVID-19 did something different.
As the healthcare system faces the onslaught of the novel coronavirus SARS-CoV-2, clinicians caring for individuals with cancer face the challenge of a wide gap in knowledge needed to guide decision-making.
On a chaotic COVID weekend two months ago, a friend’s child (a young, talented black and Latino student athlete) came home from college not feeling well. The young man’s mother, an executive administrative assistant, called off work to stay home with him because of his, as she described, “full-blown flu-like symptoms.”
FDA has approved Retevmo (selpercatinib) capsules to treat non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in patients whose tumors have an alteration in a specific gene (RET).
